CJC-1295 (no DAC) procurement brief: GHRH analogue identity and stability notes
8 min read · Research use only
Written and reviewed by BluGen Research Team · Editorial standards
This procurement brief helps laboratory purchasing and QA teams evaluate CJC-1295 (no DAC) as research-use-only material: what identity fields to confirm, what a valid lot CoA must include, how to handle receiving, and which documentation red flags should stop inventory acceptance. It is not medical, dosing, or consumer guidance.
Identity fields to confirm before accepting the lot
CJC-1295 (no DAC) is a stabilized GHRH(1-29) analogue with defined residue substitutions. Confirm “no DAC” form and MW versus Sermorelin (native GHRH(1-29)) before accepting the lot.
Match SKU, lot number, and CoA document ID before opening the outer carton. Photograph labels when your chain-of-custody SOP requires it.
What a valid CoA must show
HPLC + MS identity + net peptide content on a lot-specific CoA. Keep documentation distinct from Ipamorelin even when both SKUs ship for parallel pathway work.
Prefer suppliers that also allow public lot verification. BluGen lots can be checked in the CoA Library when published for that batch.
reconstitution-and-concentration-math">Storage, reconstitution, and concentration math
Longer sequence and methionine content increase oxidation sensitivity versus short secretagogues. Minimize open-vial time; aliquot aggressively.
Use net peptide content for molarity calculations. Gross vial mass systematically overstates active peptide when water and counter-ions are present.
Documentation red flags
Any of the following should trigger quarantine pending supplier clarification:
- DAC vs no-DAC ambiguity on the label or CoA
- Confusion with Sermorelin on receiving
- Shared reconstitution logs with Ipamorelin
Next steps
Open the CJC-1295 (no DAC) product page for SKU variants and identity tables, then read the matching research guide and any related comparison article before finalizing the PO.
Pair this brief with the supplier evaluation checklist, CoA reading guide, and reconstitution calculator for a complete receiving package.
Frequently asked questions
Is this CJC-1295 (no DAC) brief for clinical purchasing?
No. All materials discussed are research use only and are not for human or veterinary administration, diagnosis, or treatment.
What is the minimum CoA package for this SKU?
Lot-specific HPLC purity, MS identity matching the expected form, and net peptide content when concentration work is required—plus a clear lot number on vial and document.
Where do I verify a BluGen lot?
Use the public CoA Library lot lookup when the lot is published, and retain the shipment CoA in your LIMS or procurement file.
Citation
BluGen Research Peptides — CJC-1295 (no DAC) procurement brief: GHRH analogue identity and stability notes. https://getblugen.com/research/cjc-1295-research-peptide-procurement-brief/. Accessed 2026-07-21.
Products referenced in this guide
Related research
Longevity
CJC-1295 + Ipamorelin blend vs ordering components separately
Blends simplify ordering but complicate documentation. This note explains when a pre-combined CJC-1295 + Ipamorelin research listing is appropriate versus stocking components for independent concentration control.
8 min read
Longevity
Ipamorelin research peptide procurement brief: GHS-R1a secretagogue documentation
This procurement brief helps laboratory purchasing and QA teams evaluate Ipamorelin as research-use-only material: what identity fields to confirm, what a valid lot CoA must include, how to handle receiving, and which documentation red flags should stop inventory acceptance. I...
8 min read
Longevity
Sermorelin vs CJC-1295: the four residue substitutions that decide your half-life in published research
Same receptor, same 29-residue length, and a four-substitution structural difference that does almost all the work in published stability research. This is the comparison where "almost identical" actually means measurable.
8 min read